Compounds > pyrido(3,4-c)psoralen
Page last updated: 2024-11-06

pyrido(3,4-c)psoralen

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

pyrido(3,4-c)psoralen: structure given in ifrst source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID55431
CHEBI ID82528
SCHEMBL ID1115781
MeSH IDM0129428

Synonyms (21)

Synonym
5h-furo(3',2':6,7)(1)benzopyrano(3,4-c)pyridin-5-one plus ultraviolet a radiation
pyrido(3,4-c)psoralen plus ultraviolet a radiation
brn 5046981
pyrido(3,4-c)psoralen
5h-furo(3',2':6,7)(1)benzopyrano(3,4-c)pyridin-5-one, thymidylyl-(5'-3')-2'-deoxy-, (17alpha,20e)-
C19516
pyrido[3,4-c]psoralen
85878-62-2
unii-ij1oh5v1hp
ij1oh5v1hp ,
pyrido(3,4-c)furo(3,2-g)coumarin
niosh/lv1576500
9h-furo(3',2':6,7)(1)benzopyrano(3,4-c)pyridin-9-one
LV15765000 ,
CHEBI:82528
DTXSID10235189
SCHEMBL1115781
Q27156044
5h-furo[3',2':6,7]chromeno[3,4-c]pyridin-5-one
5h-furo(3',2':6,7)(1)benzopyrano(3,4-c)pyridin-5-one
pyrido(3,4-c)psoralen [iarc]
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
furanocoumarinAny furochromene that consists of a furan ring fused with a coumarin. The fusion may occur in different ways in give several isomers.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (4)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (75.00)18.7374
1990's1 (25.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.38

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.38 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.38)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (16.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (83.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
methoxsalen
Methoxsalen: A naturally occurring furocoumarin compound found in several species of plants, including Psoralea corylifolia. It is a photoactive substance that forms DNA ADDUCTS in the presence of ultraviolet A irradiation.. methoxsalen : A member of the class of psoralens that is 7H-furo[3,2-g]chromen-7-one in which the 9 position is substituted by a methoxy group. It is a constituent of the fruits of Ammi majus. Like other psoralens, trioxsalen causes photosensitization of the skin. It is administered topically or orally in conjunction with UV-A for phototherapy treatment of vitiligo and severe psoriasis.		2.3720aromatic ether;
psoralens		antineoplastic agent;
cross-linking reagent;
dermatologic drug;
photosensitizing agent;
plant metabolite
pyrido(3,4-c)-7-methylpsoralen
pyrido(3,4-c)-7-methylpsoralen: structure given in first source		2.3720furanocoumarin
pyrimidine dimers
Pyrimidine Dimers: Dimers found in DNA chains damaged by ULTRAVIOLET RAYS. They consist of two adjacent PYRIMIDINE NUCLEOTIDES, usually THYMINE nucleotides, in which the pyrimidine residues are covalently joined by a cyclobutane ring. These dimers block DNA REPLICATION.		1.9710
ConditionIndicatedRelationship StrengthStudiesTrials
Palmoplantaris Pustulosis
[description not available]		01.9610
Psoriasis
A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.		01.9610
Anemia, Hypoplastic
[description not available]		01.9610
Anemia, Fanconi
[description not available]		01.9610
Anemia, Aplastic
A form of anemia in which the bone marrow fails to produce adequate numbers of peripheral blood elements.		01.9610
Fanconi Anemia
Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)		01.9610